BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32077136)

  • 1. Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia.
    Zhou Y; Wang L; Zhai XY; Wen L; Tang F; Yang F; Liu XT; Dong L; Zhi LJ; Shi HY; Hao GX; Zheng Y; Jacqz-Aigrain E; Wang TY; Zhao W
    Br J Clin Pharmacol; 2020 Aug; 86(8):1519-1527. PubMed ID: 32077136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.
    Adam de Beaumais T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2011 Apr; 71(4):575-84. PubMed ID: 21395650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
    Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
    Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?
    Zhou H; Li L; Yang P; Yang L; Zheng JE; Zhou Y; Han Y
    BMC Cancer; 2018 May; 18(1):516. PubMed ID: 29720126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
    Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
    Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics of 6-mercaptopurine in a black Zimbabwean cohort treated for acute lymphoblastic leukaemia.
    Chikondowa P; Munkombwe D; Chikwambi Z; Kuona P; Masimirembwa C
    Pharmacogenomics; 2023 Jun; 24(8):449-457. PubMed ID: 37248698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
    Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
    Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.
    Lennard L; Welch J; Lilleyman JS
    Br J Clin Pharmacol; 1996 Oct; 42(4):525-7. PubMed ID: 8904630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
    Hawwa AF; Millership JS; Collier PS; Vandenbroeck K; McCarthy A; Dempsey S; Cairns C; Collins J; Rodgers C; McElnay JC
    Br J Clin Pharmacol; 2008 Oct; 66(4):517-28. PubMed ID: 18662289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Susceptibility to 6-mercaptopurine toxicity related with NUDT15 and ABCC4 variants in Japanese childhood acute lymphoblastic leukemia].
    Tanaka Y
    Rinsho Ketsueki; 2017; 58(8):950-956. PubMed ID: 28883280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prominence of NUDT15 genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia.
    Tanaka Y; Urayama KY; Mori M; Arakawa Y; Hasegawa D; Noguchi Y; Yanagimachi M; Keino D; Ota S; Akahane K; Inukai T; Hangai M; Kawaguchi T; Takagi M; Koh K; Matsuda F; Manabe A
    Br J Haematol; 2022 Oct; 199(2):260-269. PubMed ID: 35961941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.
    Tanaka Y; Kato M; Hasegawa D; Urayama KY; Nakadate H; Kondoh K; Nakamura K; Koh K; Komiyama T; Manabe A
    Br J Haematol; 2015 Oct; 171(1):109-15. PubMed ID: 26033531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia.
    Choi R; Sohn I; Kim MJ; Woo HI; Lee JW; Ma Y; Yi ES; Koo HH; Lee SY
    Br J Clin Pharmacol; 2019 Jul; 85(7):1585-1597. PubMed ID: 30927276
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Fan POL; Leung KT; Chan KYY; Leung AWK; Lam GKS; Chow TTW; Cheng FWT; Yuen LYP; Moriyama T; Yang JJ; Li CK
    Pediatr Hematol Oncol; 2022 Apr; 39(3):254-266. PubMed ID: 34665987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia.
    Moriyama T; Nishii R; Lin TN; Kihira K; Toyoda H; Jacob N; Kato M; Koh K; Inaba H; Manabe A; Schmiegelow K; Yang JJ; Hori H
    Pharmacogenet Genomics; 2017 Jun; 27(6):236-239. PubMed ID: 28445187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mercaptopurine induced myelosuppression in a child with a
    Gupta N; Magatha LS; Jayaraman D; Scott JX; Antony SB; Koshy T
    J Oncol Pharm Pract; 2023 Jun; 29(4):999-1001. PubMed ID: 36341754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
    Hawwa AF; Collier PS; Millership JS; McCarthy A; Dempsey S; Cairns C; McElnay JC
    Br J Clin Pharmacol; 2008 Dec; 66(6):826-37. PubMed ID: 18823306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
    Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
    Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia.
    Lancaster DL; Patel N; Lennard L; Lilleyman JS
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):33-6. PubMed ID: 12111109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of
    Nishii R; Moriyama T; Janke LJ; Yang W; Suiter CC; Lin TN; Li L; Kihira K; Toyoda H; Hofmann U; Schwab M; Takagi M; Morio T; Manabe A; Kham S; Jiang N; Rabin KR; Kato M; Koh K; Yeoh AE; Hori H; Yang JJ
    Blood; 2018 May; 131(22):2466-2474. PubMed ID: 29572377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.